DK1450847T3 - Apo2-ligand/TRAIL-formuleringer og anvendelser deraf - Google Patents

Apo2-ligand/TRAIL-formuleringer og anvendelser deraf

Info

Publication number
DK1450847T3
DK1450847T3 DK02784443.0T DK02784443T DK1450847T3 DK 1450847 T3 DK1450847 T3 DK 1450847T3 DK 02784443 T DK02784443 T DK 02784443T DK 1450847 T3 DK1450847 T3 DK 1450847T3
Authority
DK
Denmark
Prior art keywords
formulations
trail
applications
apo2 ligand
trail formulations
Prior art date
Application number
DK02784443.0T
Other languages
English (en)
Inventor
Heather Flores
Roger Pai
Zahra Shahrokh
Tanya P Lin
Timothy C Matthews
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Application granted granted Critical
Publication of DK1450847T3 publication Critical patent/DK1450847T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
DK02784443.0T 2001-11-13 2002-11-12 Apo2-ligand/TRAIL-formuleringer og anvendelser deraf DK1450847T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33824901P 2001-11-13 2001-11-13
PCT/US2002/036251 WO2003042344A2 (en) 2001-11-13 2002-11-12 Apo2 ligand/trail formulations

Publications (1)

Publication Number Publication Date
DK1450847T3 true DK1450847T3 (da) 2010-12-13

Family

ID=23324037

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02784443.0T DK1450847T3 (da) 2001-11-13 2002-11-12 Apo2-ligand/TRAIL-formuleringer og anvendelser deraf

Country Status (11)

Country Link
US (3) US7741282B2 (da)
EP (3) EP2332531B1 (da)
JP (2) JP2005521640A (da)
AT (1) ATE482716T1 (da)
CA (1) CA2466054C (da)
DE (1) DE60237841D1 (da)
DK (1) DK1450847T3 (da)
ES (1) ES2351786T3 (da)
IL (3) IL161812A0 (da)
PT (1) PT1450847E (da)
WO (1) WO2003042344A2 (da)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001000832A1 (en) * 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations
KR20050090430A (ko) 2002-12-31 2005-09-13 알투스 파마슈티컬스 인코포레이티드 인간 성장 호르몬 결정 및 이것의 제조 방법
ZA200505306B (en) * 2002-12-31 2006-09-27 Altus Pharmaceuticals Inc Complexes of protein crystals and ionic polymers
US20060019234A1 (en) * 2004-07-22 2006-01-26 Shanbrom Technologies, Llc Modern blood banking employing improved cell preservation composition
US20060051347A1 (en) * 2004-09-09 2006-03-09 Winter Charles M Process for concentration of antibodies and therapeutic products thereof
US20090155247A1 (en) * 2005-02-18 2009-06-18 Ashkenazi Avi J Methods of Using Death Receptor Agonists and EGFR Inhibitors
US20060188498A1 (en) * 2005-02-18 2006-08-24 Genentech, Inc. Methods of using death receptor agonists and EGFR inhibitors
CA2611200A1 (en) * 2005-06-06 2006-12-14 Novo Nordisk A/S Stabilised il-21 compositions
ATE533058T1 (de) * 2005-08-16 2011-11-15 Genentech Inc Apoptosesensitivität gegenüber apo2l/trail mittels testen auf galnac-t14-expression in zellen/gewebe
US9309316B2 (en) 2005-12-20 2016-04-12 Bristol-Myers Squibb Company Stable subcutaneous protein formulations and uses thereof
ES2436616T5 (es) * 2005-12-20 2022-05-27 Bristol Myers Squibb Co Formulaciones proteicas estables
GB0710529D0 (en) 2007-06-01 2007-07-11 Circassia Ltd Vaccine
SI2190473T1 (sl) 2007-08-15 2013-05-31 Circassia Limited Peptid z zmanjšano tvorbo dimerov
WO2009040811A2 (en) * 2007-09-24 2009-04-02 Bar-Ilan University Polymer nanoparticles coated by magnetic metal oxide and uses thereof
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
DK2350271T3 (da) 2008-11-20 2016-04-04 Biogen Ma Inc Arginininaktivering af omhyllede vira
GB0821806D0 (en) 2008-11-28 2009-01-07 Circassia Ltd Compositions with reduced dimer formation
DE102008064553B4 (de) * 2008-12-22 2015-05-13 Technische Universität Dresden Verfahren zum Nachweis und/oder zur Identifizierung hormonell wirksamer Substanzen
US9052304B2 (en) 2009-03-13 2015-06-09 Terrasep, Llc Methods and apparatus for centrifugal liquid chromatography
EP4328305A3 (en) 2009-12-18 2024-08-14 CSL Ltd. Method of purifying polypeptides
EP2563809B1 (en) * 2010-04-27 2020-04-01 Scil Technology GmbH Stable aqueous mia/cd-rap formulations
BR112012027828A2 (pt) * 2010-05-03 2016-08-09 Genentech Inc composição de matéria, artigo de fabricação e método de redução da viscosidade de uma formulação contendo proteína e de preparação de uma formulação aquosa contendo proteína
WO2012151317A1 (en) 2011-05-03 2012-11-08 Genentech, Inc. Vascular disruption agents and uses thereof
SG11201406664SA (en) * 2012-05-11 2014-11-27 Novartis Ag Crystallization methods for purification of monoclonal antibodies
WO2014199373A1 (en) * 2013-06-09 2014-12-18 Efranat Ltd. Compositions comprising gc- macrophage activating factor and uses thereof
US11279768B1 (en) 2015-04-03 2022-03-22 Precision Biologics, Inc. Anti-cancer antibodies, combination therapies, and uses thereof
US10501744B2 (en) 2016-05-04 2019-12-10 Indiana University Research And Technology Corporation Presentation of bioactive proteins
KR20210119385A (ko) * 2018-12-21 2021-10-05 아이크노스 사이언스 에스. 아. 세포 배양물 정화 방법

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
JPS5829958B2 (ja) * 1977-03-07 1983-06-25 工業技術院長 タンパク質結晶の形成方法
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
AU2353384A (en) 1983-01-19 1984-07-26 Genentech Inc. Amplification in eukaryotic host cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
DD266710A3 (de) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Verfahren zur biotechnischen Herstellung van alkalischer Phosphatase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
JPS60126084A (ja) * 1983-12-13 1985-07-05 Toyo Jozo Co Ltd グリセロリン酸オキシダーゼの安定化法
JPS62283932A (ja) 1986-05-29 1987-12-09 Green Cross Corp:The 組織プラスミノ−ゲンアクチベ−タの乾燥製剤
ES2032831T5 (es) 1986-08-19 2001-02-16 Genentech Inc Dispositivo y dispersion para suministro intrapulmonar de factores de crecimiento polipeptidos y citoquinas.
JP2602850B2 (ja) * 1987-10-27 1997-04-23 富士通株式会社 単結晶作製方法
JPH04501201A (ja) 1987-12-21 1992-03-05 ジ・アップジョン・カンパニー 発芽植物種子類のアグロバクテリウム媒介形質転換
DK168302B1 (da) 1989-06-29 1994-03-07 Danisco Fremgangsmåde til indføring af molekyler, især genetisk materiale i planteceller
EP1132471A3 (de) 1989-09-12 2001-11-28 F. Hoffmann-La Roche Ag TNF-bindende Proteine
US5206161A (en) 1991-02-01 1993-04-27 Genentech, Inc. Human plasma carboxypeptidase B
CH682806A5 (de) 1992-02-21 1993-11-30 Medimpex Ets Injektionsgerät.
JP3007785B2 (ja) * 1993-03-16 2000-02-07 旭化成工業株式会社 トロンボモジュリン組成物およびその変性防止方法
US6284236B1 (en) 1995-06-29 2001-09-04 Immunex Corporation Cytokine that induces apoptosis
US5763223A (en) * 1995-06-29 1998-06-09 Immunex Corporation DNA encoding a cytokine that induces apoptosis
US6030945A (en) 1996-01-09 2000-02-29 Genentech, Inc. Apo-2 ligand
TW518219B (en) 1996-04-26 2003-01-21 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
ATE302272T1 (de) 1996-10-25 2005-09-15 Human Genome Sciences Inc Neutrokin alpha
JP2002509431A (ja) 1996-12-23 2002-03-26 イミュネックス・コーポレーション ＮＦ−κＢのレセプター活性化因子−レセプターはＴＮＦレセプタースーパーファミリーの一員である−
WO1998032856A1 (en) 1997-01-28 1998-07-30 Human Genome Sciences, Inc. Death domain containing receptor 4 (dr4: death receptor 4), member of the tnf-receptor superfamily and binding to trail (ap02-l)
US6072047A (en) 1997-02-13 2000-06-06 Immunex Corporation Receptor that binds trail
US20010010924A1 (en) 1997-03-14 2001-08-02 Keith Charles Deen Tumor necrosis factor related receptor, tr6 polynecleotides
CA2644454A1 (en) 1997-03-17 1998-09-24 Human Genome Sciences, Inc. Death domain containing receptor 5
US6140475A (en) * 1997-04-11 2000-10-31 Altus Biologics Inc. Controlled dissolution crosslinked protein crystals
JP2002512515A (ja) 1997-04-16 2002-04-23 ミレニアム ファーマシューティカルズ インク． 腫瘍壊死因子受容体関連蛋白質ＴＡＮＧＯ−６３ｄおよびＴＡＮＧＯ−６３ｅ
EP1717315A3 (en) 1997-04-16 2007-06-20 Amgen Inc. Osteoprotegerin binding proteins and receptors
DK1860187T3 (da) 1997-05-15 2011-10-31 Genentech Inc Apo-2-receptor
EP1032661A1 (en) 1997-06-18 2000-09-06 Genentech, Inc. Apo-2DcR
CA2294729C (en) 1997-07-02 2003-05-06 The Procter & Gamble Company Suspension for adding a controlled amount of ingredient to a food product
WO1999002653A1 (en) 1997-07-11 1999-01-21 Trustees Of The University Of Pennsylvania Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use
WO1999006673A1 (en) 1997-07-30 1999-02-11 Eg & G Sealol, Inc. Improved brush seal and method of making same
US6417328B2 (en) 1997-08-15 2002-07-09 Thomas Jefferson Univeristy Trail receptors, nucleic acids encoding the same, and methods of use thereof
DK1009817T3 (da) 1997-08-26 2010-01-18 Genentech Inc RTD-receptor
WO1999011791A2 (en) 1997-09-05 1999-03-11 University Of Washington Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
DE69939732D1 (de) 1998-01-15 2008-11-27 Genentech Inc Apo-2 ligand
JP4194681B2 (ja) * 1998-01-20 2008-12-10 太陽化学株式会社 可溶性γ−リベチン複合体の製造法
PT1064027E (pt) 1998-03-27 2008-09-29 Genentech Inc Sinergismo de ligando de apo-2 e anticorpo anti-her-2
GB2349636A (en) 1998-09-17 2000-11-08 Adv Liquid Packaging Corp Resealable can
FR2783596B1 (fr) 1998-09-23 2001-03-09 Eurokera Ensemble prefabrique destine a la realisation de tables de cuisson
WO2000075191A2 (en) 1999-06-09 2000-12-14 Genentech, Inc. Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM
WO2001000832A1 (en) 1999-06-28 2001-01-04 Genentech, Inc. Methods for making apo-2 ligand using divalent metal ions
AUPQ312699A0 (en) 1999-09-28 1999-10-21 Electrical Moulded Components Pacific Pty Ltd Electrical reticulation apparatus
CA2386002A1 (en) 1999-09-30 2001-04-05 The Trustees Of The University Of Pennsylvania Trail: an inhibitor of autoimmune inflammation and cell cycle progression
BRPI0017437B8 (pt) 1999-10-04 2021-05-25 Chiron Corp composição farmacêutica estabilizada contendo polipeptídeo il-2, método para aumentar estabilidade de interleucina-2 em uma composição farmacêutica, e uma forma seca da composição
DK1129720T3 (da) * 2000-02-29 2004-09-27 Pfizer Prod Inc Stabiliseret granulocyt-kolonistimulerende faktor
JP2004509078A (ja) 2000-07-27 2004-03-25 ジェネンテック・インコーポレーテッド Ａｐｏ−２ＬレセプターアゴニストとＣＰＴ−１１の相乗作用
IL161051A0 (en) * 2001-10-02 2004-08-31 Genentech Inc Apo-2 ligand variants and uses thereof
US7741285B2 (en) * 2001-11-13 2010-06-22 Genentech, Inc. APO-2 ligand/trail formulations

Also Published As

Publication number Publication date
DE60237841D1 (de) 2010-11-11
US20050080006A1 (en) 2005-04-14
EP1450847A2 (en) 2004-09-01
PT1450847E (pt) 2011-01-05
US20110269947A1 (en) 2011-11-03
US8470969B2 (en) 2013-06-25
JP2005521640A (ja) 2005-07-21
EP2332531A1 (en) 2011-06-15
CA2466054C (en) 2012-01-03
WO2003042344A2 (en) 2003-05-22
JP2009108040A (ja) 2009-05-21
WO2003042344A3 (en) 2003-11-27
EP2322165A1 (en) 2011-05-18
US7741282B2 (en) 2010-06-22
IL197705A0 (en) 2009-12-24
ATE482716T1 (de) 2010-10-15
JP5042959B2 (ja) 2012-10-03
IL161812A (en) 2013-02-28
EP1450847A4 (en) 2007-08-29
ES2351786T3 (es) 2011-02-10
EP2332531B1 (en) 2019-07-10
EP1450847B1 (en) 2010-09-29
CA2466054A1 (en) 2003-05-22
US20050020498A1 (en) 2005-01-27
IL161812A0 (en) 2005-11-20

Similar Documents

Publication Publication Date Title
DK1450847T3 (da) Apo2-ligand/TRAIL-formuleringer og anvendelser deraf
HK1131744A1 (en) Toll like receptor 3 antagonists, methods and uses toll
DE60325892D1 (de) Stellungs- und verwendungsverfahren
MXPA03008754A (es) Derivados de piridina fundidos para utilizarse como agonistas receptores vaniloide para tratar dolor.
EP1649006A4 (en) EXO-SPECIFIC AMYLASE POLYPEPTIDES, THESE POLYPEPTIDE-CODING NUCLEIC ACIDS, AND USES THEREOF
DK1343782T3 (da) Pyrimidinaminer som angiogenesemodulatorer
TW200611910A (en) Interferon-alpha polypeptides and conjugates
WO2007051164A8 (en) Toll like receptor 3 modulators, methods and uses
DK1131444T3 (da) Polypeptider med lysophospholipase aktivitet og nucleinsyre som koder for disse
DK1083903T3 (da) Brobundne indenopyrrolocarbazoler
DE60226852D1 (de) Lentivirale verpackungskonstrukte
WO2004000859A3 (en) Etoposide analogs and methods of use thereof
WO2004046365A3 (en) Interferon-alpha polypeptides and conjugates
DK1519944T3 (da) Fremgangsmåder til fremstilling af fibrinogen
WO2004087874A3 (en) Novel nucleic acids and polypeptides
DE60204701D1 (de) Tricyclische imidazopyridine
DK1680430T3 (da) Fremgangsmåder til fremstilling af form I af (S)-(+)-Clopidogrel-bisulfat
NO20012461D0 (no) Krystallmodifikasjon B av 8-cyano-1-cyklopropyl-7-(1S,6S-2,8- diazabicyklo(4.3.0)nonan-8-yl)-6-fluor-1,4-dihydro-4-okso-3-quinolinkarboksylsyre
ATE280802T1 (de) Thermisch stabilisierte pvc-zusammensetzungen
DE602004030231D1 (de) Pyrimidinonverbindungen als calcilytica
EP1436279A4 (en) CHEMICAL COMPOUNDS
WO2005057486A3 (en) Protein engineering with analogous contact environments
SE0101700D0 (sv) Nucleotide sequences
WO2000068240A8 (en) NOVEL aroA